文献类型：期刊文献

英文题名：Synthesis of glucosamine-selenium compound and evaluation of its oral toxicity and in vitro anti-hepatitis B virus activity

作者：Ding, Hong[1];Lu, Xiaoxuan[1];Ji, Xiaoguo[1];Wang, Shijie[2];Jin, Jiayang[1];Zhao, Mengyao[1];Hang, Xiaofeng[2];Zhao, Liming[1,2,3]

机构：[1]East China Univ Sci & Technol, R&D Ctr Separat & Extract Technol Fermentat Ind, Sch Biotechnol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]Shanghai Changzheng Hosp, Shanghai 200003, Peoples R China;[3]Shanghai Collaborat Innovat Ctr Biomfg Technol SCI, Shanghai 200237, Peoples R China

年份：2024

卷号：402

外文期刊名：CHEMICO-BIOLOGICAL INTERACTIONS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001295841000001)】；

基金：This study was endorsed by the China Postdoctoral Science Foundation (2023M731087) , Shanghai Sailing Program (23YF1409800) , Natural Science Foundation of Shanghai (23ZR1415400) and Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism (Shanghai Municipal Education Commission) .

语种：英文

外文关键词：Glucosamine selenium; Oral toxicity; Acute toxicity; Subchronic toxicity; Anti-hepatitis B activity

摘要：Selenium supplements are beneficial to human health, however, concerns regarding the toxicity of inorganic selenium have stimulated research on safer organic compounds. The main objective of this study was to develop a novel glucosamine-selenium compound (Se-GlcN), clarify its structure, and subsequently investigate its oral toxicity and in vitro anti-hepatitis B virus (HBV) activity. Electron microscopy, infrared, ultraviolet spectroscopy, nuclear magnetic resonance and thermogravimetric analyses revealed a unique binding mode of Se-GlcN, with the introduction of the Se-O bond at the C6 position, resulting in the formation of two carboxyl groups. In acute toxicity studies, the median lethal dose (LD50) of Se-GlcN in ICR mice was 92.31 mg/kg body weight (BW), with a 95% confidence interval of 81.88-104.07 mg/kg BW. A 30-day subchronic toxicity study showed that 46.16 mg/ kg BW Se-GlcN caused livers and kidneys damage in mice, whereas doses of 9.23 mg/kg BW and lower were safe for the livers and kidneys. In vitro studies, Se-GlcN at 1.25 mu g/mL exhibited good anti-HBV activity, significantly reducing HBsAg, HBeAg, 3.5 kb HBV RNA and total HBV RNA by 45 %, 54 %, 84 %, 87 %, respectively. In conclusion, the Se-GlcN synthesized in this study provides potential possibilities and theoretical references for its use as an organic selenium supplement.